Table 4.
Summary of steady-state pharmacokinetic parameters for ziprasidone according to age.
| Mean | Difference between means (95% CI) | |||
|---|---|---|---|---|
| Young | Elderly | P value | ||
| Analysis of variance | ||||
| AUC(0,12 h)a (ng ml−1 h) | 465 | 560 | 120% (100.9, 143.6) | 0.040 |
| Cmaxa (ng ml−1) | 69 | 85 | 122% (100.5, 148.9) | 0.045 |
| λz (h−1) | 0.197 | 0.126 | −0.071 (−0.104, −0.038) | 0.0001 |
| tmax (h) | 3.63 | 4.38 | 0.75 (−0.41, 1.91) | 0.194 |
| Analysis of covariance | ||||
| AUC(0,12 h)a (ng ml−1 h) | 469 | 555 | 118% (99.6, 140.4) | 0.056 |
| Cmaxa (ng ml−1) | 70 | 84 | 120% (99.1, 146.5) | 0.062 |
a
The difference between geometric means for AUC(0,12 h) and Cmax was represented by the ratio between geometric means and the 95% confidence interval (CI) around the ratio.